SCHEDULE 13G/A: Ameriprise Financial and Affiliates Disclose Significant Stake in Altimmune, Inc.

Ameriprise Financial, Inc. and its affiliated entities, including Threadneedle Asset Management, have reported beneficial ownership of 7.4% of Altimmune, Inc.'s common stock as of December 31, 2024.

Summary

• Ameriprise Financial, Inc. and its affiliated entities, collectively referred to as the "Ameriprise Entities," have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Altimmune, Inc.
• As of December 31, 2024, Ameriprise Financial, Inc. beneficially owns an aggregate of 5,254,898 shares of Altimmune, Inc. common stock, representing 7.4% of the class.
• Ameriprise Financial, Inc. holds shared voting power over 5,240,321 shares and shared dispositive power over 5,254,898 shares.
• Several UK-based Threadneedle and TAM UK entities, which are subsidiaries of Ameriprise, each report beneficial ownership of 5,100,663 shares, representing 7.2% of the class.
• These Threadneedle and TAM UK entities hold shared voting and dispositive power over their reported 5,100,663 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Altimmune, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership by institutional investors and does not contain information that would indicate a positive or negative sentiment regarding the issuer's operational or financial performance. The presence of significant institutional ownership is generally viewed as a neutral to slightly positive signal for investor confidence.

Positives

• Significant institutional investment from Ameriprise Financial and its affiliates, indicating a level of confidence in Altimmune, Inc.
• The filing explicitly states that the shares were acquired and are held in the ordinary course of business, not for control-influencing purposes, suggesting a passive and long-term investment stance.

Stakeholder Impact

• Shareholders: Provides transparency on significant institutional holdings, which can influence market perception and liquidity.
• Investors: Offers insight into major institutional positions, potentially signaling confidence or strategic interest in Altimmune, Inc.

Key Dates

Keywords

Altimmune, Ameriprise Financial, Threadneedle, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional investment, equity stake